Drugs / BW-41012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07584876 | May 2026 → Oct 2027 expected | — | Shanghai Argo Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | Shanghai Argo Biopharmaceutical Co., Ltd. | Argo Biopharma Doses First Participant in Phase I Clinical Trial of Factor XI Targeting siRNA Therapy BW-41012 argobiopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BW-41012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07584876 ↗ |
| Route | Subcutaneous | “route of administration is subcutaneous injection” NCT07584876 ↗ |